EA022434B9 - Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент - Google Patents
Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагментInfo
- Publication number
- EA022434B9 EA022434B9 EA201301114A EA201301114A EA022434B9 EA 022434 B9 EA022434 B9 EA 022434B9 EA 201301114 A EA201301114 A EA 201301114A EA 201301114 A EA201301114 A EA 201301114A EA 022434 B9 EA022434 B9 EA 022434B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- phosphoinositide
- kinase inhibitor
- binding moiety
- zinc binding
- kinase
- Prior art date
Links
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 230000004572 zinc-binding Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470849P | 2011-04-01 | 2011-04-01 | |
| US201161559489P | 2011-11-14 | 2011-11-14 | |
| PCT/US2012/031361 WO2012135571A1 (en) | 2011-04-01 | 2012-03-30 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201301114A1 EA201301114A1 (ru) | 2014-04-30 |
| EA022434B1 EA022434B1 (ru) | 2015-12-30 |
| EA022434B9 true EA022434B9 (ru) | 2016-02-29 |
Family
ID=46931927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201301114A EA022434B9 (ru) | 2011-04-01 | 2012-03-30 | Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8710219B2 (enExample) |
| EP (2) | EP2694075B1 (enExample) |
| JP (3) | JP6242331B2 (enExample) |
| KR (2) | KR101902325B1 (enExample) |
| CN (2) | CN105461736B (enExample) |
| AU (1) | AU2012236367B2 (enExample) |
| BR (1) | BR112013025340B1 (enExample) |
| CA (1) | CA2830822C (enExample) |
| CL (1) | CL2013002823A1 (enExample) |
| CY (2) | CY1117785T1 (enExample) |
| DK (2) | DK2694075T3 (enExample) |
| EA (1) | EA022434B9 (enExample) |
| ES (2) | ES2577982T3 (enExample) |
| HR (2) | HRP20160545T1 (enExample) |
| HU (2) | HUE028910T2 (enExample) |
| IL (2) | IL228588A (enExample) |
| LT (1) | LT3111938T (enExample) |
| ME (2) | ME02451B (enExample) |
| MX (1) | MX340577B (enExample) |
| PE (1) | PE20141382A1 (enExample) |
| PL (2) | PL2694075T3 (enExample) |
| PT (2) | PT2694075T (enExample) |
| RS (2) | RS54903B1 (enExample) |
| SG (2) | SG193563A1 (enExample) |
| SI (2) | SI2694075T1 (enExample) |
| SM (2) | SMT201900435T1 (enExample) |
| TW (1) | TWI571469B (enExample) |
| WO (1) | WO2012135571A1 (enExample) |
| ZA (2) | ZA201307082B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54230B1 (sr) | 2009-01-08 | 2015-12-31 | Curis Inc. | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| ME02451B (me) | 2011-04-01 | 2016-09-20 | Curis Inc | Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| JP6051434B2 (ja) | 2011-11-14 | 2016-12-27 | イグニタ、インク． | ＡＸＬおよびｃ−ＭＥＴキナーゼ阻害剤としてのウラシル誘導体 |
| CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
| ES2833473T3 (es) * | 2015-04-21 | 2021-06-15 | Chengdu Zenitar Biomedical Tech Co Ltd | Derivados de purinil-N-hidroxil pirimidin formamida, método de preparación y uso de los mismos |
| WO2018015895A1 (en) * | 2016-07-19 | 2018-01-25 | National Institute Of Plant Genome Research | Novel protein against fungal pathogens |
| CN109923117A (zh) * | 2016-11-02 | 2019-06-21 | 柯瑞斯公司 | 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗 |
| US11406647B2 (en) * | 2017-11-06 | 2022-08-09 | Cold Spring Harbor Laboratory | Method and compositions for forming a copper-containing complex and uses thereof |
| MX2021002742A (es) | 2018-09-11 | 2021-08-11 | Curis Inc | Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc. |
| EP3968215A1 (en) | 2020-09-09 | 2022-03-16 | Koninklijke Philips N.V. | Determining target object type and position |
| WO2023212574A1 (en) * | 2022-04-26 | 2023-11-02 | Olivia Szu Hsieh Lee Nakaya | Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100222343A1 (en) * | 2009-01-08 | 2010-09-02 | Xiong Cai | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP4648628B2 (ja) | 2002-03-13 | 2011-03-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体 |
| PL212089B1 (pl) | 2002-03-13 | 2012-08-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja |
| MY140390A (en) | 2002-03-13 | 2009-12-31 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase |
| MXPA04007775A (es) | 2002-03-13 | 2004-10-15 | Janssen Pharmaceutica Nv | Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa. |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| PL214756B1 (pl) | 2003-01-29 | 2013-09-30 | Takeda Pharmaceutical | Zwiazki tienopirymidynowe, kompozycja farmaceutyczna zawierajaca te zwiazki oraz ich zastosowanie |
| JP4993374B2 (ja) * | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| US7557112B2 (en) | 2004-10-08 | 2009-07-07 | Astellas Pharma Inc. | Aromatic-ring-fused pyrimidine derivative |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| NZ599464A (en) | 2005-02-03 | 2014-03-28 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors |
| ES2553178T3 (es) | 2005-05-18 | 2015-12-04 | Janssen Pharmaceutica N.V. | Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa |
| CN101370791B (zh) | 2006-01-19 | 2012-05-02 | 詹森药业有限公司 | 作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物 |
| AU2007206941B2 (en) | 2006-01-19 | 2012-09-13 | Janssen Pharmaceutica N.V. | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
| CA2630717C (en) | 2006-01-19 | 2015-02-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| ES2347187T3 (es) | 2006-04-26 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k. |
| CA2650295C (en) * | 2006-04-26 | 2015-12-29 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| BRPI0710943A2 (pt) | 2006-04-26 | 2012-06-26 | Genentech Inc | compostos farmacêuticos |
| US20100016435A1 (en) | 2006-05-16 | 2010-01-21 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| US8604044B2 (en) | 2006-09-11 | 2013-12-10 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2008033745A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| KR20090077914A (ko) | 2006-09-11 | 2009-07-16 | 쿠리스 인코퍼레이션 | 항증식제로서의 다작용성 소분자 |
| US7928136B2 (en) | 2006-09-11 | 2011-04-19 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
| CA2662580C (en) | 2006-09-11 | 2013-05-21 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
| US7888352B2 (en) | 2006-12-07 | 2011-02-15 | Piramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| AU2007333243B2 (en) | 2006-12-07 | 2013-03-14 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| RU2009134223A (ru) | 2007-02-15 | 2011-03-20 | Новартис АГ (CH) | Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака |
| US20080234332A1 (en) | 2007-03-20 | 2008-09-25 | Xiong Cai | Raf kinase inhibitors containing a zinc binding moiety |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US8247397B2 (en) * | 2007-09-12 | 2012-08-21 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| CN101909631B (zh) * | 2007-10-25 | 2012-09-12 | 健泰科生物技术公司 | 制备噻吩并嘧啶化合物的方法 |
| US20090149511A1 (en) | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
| WO2010008847A2 (en) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| US8196911B2 (en) | 2008-10-27 | 2012-06-12 | Honda Motor Co., Ltd. | Adjustable rate subframe mount |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| CA2753285A1 (en) | 2009-03-12 | 2010-09-16 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| TWI428336B (zh) | 2009-10-12 | 2014-03-01 | Hoffmann La Roche | Ｐｉ３ｋ抑制劑及ｍｅｋ抑制劑之組合 |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
| ME02451B (me) * | 2011-04-01 | 2016-09-20 | Curis Inc | Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| TW202114735A (zh) | 2011-08-01 | 2021-04-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| EP3313443B9 (en) | 2015-06-25 | 2023-10-04 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CN109923117A (zh) * | 2016-11-02 | 2019-06-21 | 柯瑞斯公司 | 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗 |
-
2012
- 2012-03-30 ME MEP-2016-116A patent/ME02451B/me unknown
- 2012-03-30 EA EA201301114A patent/EA022434B9/ru unknown
- 2012-03-30 PL PL12764605.7T patent/PL2694075T3/pl unknown
- 2012-03-30 PE PE2013002160A patent/PE20141382A1/es active IP Right Grant
- 2012-03-30 CA CA2830822A patent/CA2830822C/en active Active
- 2012-03-30 BR BR112013025340-1A patent/BR112013025340B1/pt active IP Right Grant
- 2012-03-30 RS RS20160457A patent/RS54903B1/sr unknown
- 2012-03-30 KR KR1020137028748A patent/KR101902325B1/ko active Active
- 2012-03-30 WO PCT/US2012/031361 patent/WO2012135571A1/en not_active Ceased
- 2012-03-30 SG SG2013070883A patent/SG193563A1/en unknown
- 2012-03-30 SG SG10201602569RA patent/SG10201602569RA/en unknown
- 2012-03-30 PT PT127646057T patent/PT2694075T/pt unknown
- 2012-03-30 EP EP12764605.7A patent/EP2694075B1/en active Active
- 2012-03-30 CN CN201610034817.XA patent/CN105461736B/zh active Active
- 2012-03-30 SI SI201230597A patent/SI2694075T1/sl unknown
- 2012-03-30 HU HUE12764605A patent/HUE028910T2/en unknown
- 2012-03-30 DK DK12764605.7T patent/DK2694075T3/en active
- 2012-03-30 ES ES12764605.7T patent/ES2577982T3/es active Active
- 2012-03-30 SI SI201231625T patent/SI3111938T1/sl unknown
- 2012-03-30 EP EP16166266.3A patent/EP3111938B1/en active Active
- 2012-03-30 JP JP2014502821A patent/JP6242331B2/ja active Active
- 2012-03-30 HU HUE16166266A patent/HUE045041T2/hu unknown
- 2012-03-30 PT PT16166266T patent/PT3111938T/pt unknown
- 2012-03-30 ME MEP-2019-179A patent/ME03523B/me unknown
- 2012-03-30 HR HRP20160545TT patent/HRP20160545T1/hr unknown
- 2012-03-30 ES ES16166266T patent/ES2733128T3/es active Active
- 2012-03-30 SM SM20190435T patent/SMT201900435T1/it unknown
- 2012-03-30 KR KR1020187026847A patent/KR20180108848A/ko not_active Ceased
- 2012-03-30 LT LTEP16166266.3T patent/LT3111938T/lt unknown
- 2012-03-30 CN CN201280026400.9A patent/CN103582483B/zh active Active
- 2012-03-30 AU AU2012236367A patent/AU2012236367B2/en active Active
- 2012-03-30 TW TW101111283A patent/TWI571469B/zh active
- 2012-03-30 RS RSP20190842 patent/RS59219B1/sr unknown
- 2012-03-30 MX MX2013011132A patent/MX340577B/es active IP Right Grant
- 2012-03-30 DK DK16166266.3T patent/DK3111938T3/da active
- 2012-03-30 PL PL16166266T patent/PL3111938T3/pl unknown
- 2012-03-30 US US13/435,062 patent/US8710219B2/en active Active
-
2013
- 2013-09-19 ZA ZA2013/07082A patent/ZA201307082B/en unknown
- 2013-09-29 IL IL228588A patent/IL228588A/en active IP Right Grant
- 2013-09-30 CL CL2013002823A patent/CL2013002823A1/es unknown
-
2014
- 2014-03-05 US US14/197,769 patent/US9249156B2/en active Active
- 2014-08-21 ZA ZA2014/06167A patent/ZA201406167B/en unknown
-
2015
- 2015-12-28 US US14/979,887 patent/US9657032B2/en active Active
-
2016
- 2016-06-16 SM SM201600179T patent/SMT201600179B/it unknown
- 2016-07-14 CY CY20161100683T patent/CY1117785T1/el unknown
- 2016-08-08 JP JP2016155625A patent/JP6275784B2/ja active Active
- 2016-10-30 IL IL248597A patent/IL248597B/en active IP Right Grant
-
2017
- 2017-04-25 US US15/496,318 patent/US10111864B2/en active Active
-
2018
- 2018-01-10 JP JP2018001910A patent/JP2018052987A/ja not_active Withdrawn
- 2018-10-03 US US16/150,845 patent/US10543197B2/en active Active
-
2019
- 2019-06-17 HR HRP20191091TT patent/HRP20191091T1/hr unknown
- 2019-07-17 CY CY20191100760T patent/CY1121825T1/el unknown
-
2020
- 2020-01-07 US US16/736,081 patent/US11135205B2/en active Active
-
2021
- 2021-09-09 US US17/470,410 patent/US11654136B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100222343A1 (en) * | 2009-01-08 | 2010-09-02 | Xiong Cai | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA022434B9 (ru) | Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент | |
| IN2014DN05772A (enExample) | ||
| MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
| MY151556A (en) | Organic compounds | |
| EA024702B8 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| IN2014MN00988A (enExample) | ||
| IN2014MN01183A (enExample) | ||
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| NZ626618A (en) | Hydroxamic acid derivatives and uses thereof | |
| PH12012501719A1 (en) | Compounds for immunoproteasome inhibition | |
| BR112012008073A2 (pt) | compostos heterocíclicos como inibidores de janus quinase | |
| NZ730134A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| PH12012502138B1 (en) | N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives | |
| UY31770A1 (es) | Inhibidores de catepsina c | |
| GEP20146131B (en) | Carbazole compounds and therapeutic uses thereof | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| HK1211947A1 (en) | Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors | |
| PH12012501813A1 (en) | Iap bir domain binding compounds | |
| WO2012061754A3 (en) | Compounds and methods for treating autoimmune diseases | |
| MX2012000177A (es) | 2-carboxamida-cicloamino-ureas sustituidas. | |
| MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| MX343540B (es) | Compuesto de tiazol y metodo de preparacion y uso del mismo. | |
| MX2013002620A (es) | Novedosas n-hidroxi-benzamidas para el tratamiento del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent |